PDCD1 and neoplasm: Use of checkpoint inhibitors in T cell malignancies poses concerns as although there is an anti-tumor effect on the cytotoxic T cells, there could also be an unintended blocking of PD-1 driven tumor suppression maintained by the PD-L1 expressed on the antigen presenting cells.